Advanced and Recurrent Malignant Lymphoma Were Treated by BEAC Regimen Supported with Autologous Hemotopoietic Stem Cells Transplantation
10.3321/j.issn:1000-467X.2001.04.012
- VernacularTitle:自体造血干细胞移植支持下BEAC方案治疗晚期复发恶性淋巴瘤
- Author:
Hui-Qiang HUANG
1
;
Zhong-Zhen GUAN
;
You-Jiang HE
;
Wen-Qi JIANG
;
Xiao-Fei SUN
;
Dong-Geng LIU
;
Rui-Hua XU
;
Li ZHANG
;
Zhong-Mei ZHOU
;
Tong-Yu LIN
;
Yu-Hong LI
Author Information
1. Sun Yat-sen University of Medical Sciences
- From:Chinese Journal of Cancer
2001;20(4):394-398
- CountryChina
- Language:Chinese
-
Abstract:
Objectives: High dose chemotherapy supported therapeutic outcome by AHSCT has developed dramatically in recent years and become the most effective approach to improve for the chemo-sensitive lymphoma. The purpose of this study was to evaluate the efficacy of mobilization regimen, effectiveness and tolerance of BEAC regimen in Chinese patients with advanced and recurrent lymphoma,and hemotopoietic reconstitution. Methods: After confirmed complete or partial remission from conventional chemotherapy, 20 patients with advanced or recurrent lymphoma, 1 recurrent HD and 19 NHL;14 male and 6 female with median age 28(range,13-48)years old， were enrolled into this study and treated with BEAC regimen(CTX 3600-4000 mg/m2, VP-16 1200 mg/m2. BCNU 300 mg/m2 and Ara-C 1500-2000 mg/m2). Three patients were supported by ABMT and 17 by APBSCT. Mobilization regimen for APBSCT was CTX 3500 mg/m2＋ G-CSF 3.5-5 μ g/kg＋ Dexamethasone 10 mg. Autologous hemotopoietic stem cells was re-infused 24-48 hours after completion of high dose chemotherapy. Results: MNC 1.3(range,1.0～1.7)× 108/kg and,MNC 1.8(range,1.0-4.4)× 109, CFU-GM 5.1(range,1.9-9.6)× 105/kg and CD34＋ cells 2.9 (range,1.9～8.7)× 106/kg were re-infused in the ABMT group and APBSCT group respectively. All patients obtained prompt and sustained hemotopoietic reconstitution. ANC ≥ 0.5× 109/L and Pt ≥ 2.0× 109/L were at day 9 (range,6～17) and day 10 (range,0～31) respectively. Fourteen patients were alive with median 18(range,1～67)months follow-up till end of April,2000. The 1,2,and 3 years survival rate were 61.2％ , 53.4％ and 53.4％ ,respectively. Non-hemotologic toxicity was mild and tolerable. Conclusion: High dose chemotherapy supported by AHSCT in the treatment of poor-prognostic and recurrent lymphoma is a safe and effective modality. However further investigation is warranted.
